Bought Out Or Standalone, These 4 Potential Biotech Takeover Targets Are Attractive Picks

After a down year for M&A activity in the biotech industry, 2021 is expected to see greater deal volume – and the four biotechs highlighted in today’s article could be among the takeover targets. And even if they aren’t bought out, the author sees them as attractive entities on a standalone basis. For these four biotech stocks, CLICK HERE.